410 related articles for article (PubMed ID: 33988237)
1. Extramedullary multiple myeloma patient-derived orthotopic xenograft with a highly altered genome: combined molecular and therapeutic studies.
Farre L; Sanz G; Ruiz-Xivillé N; Castro de Moura M; Martin-Tejera JF; Gonçalves-Ribeiro S; Martinez-Iniesta M; Calaf M; Luis Mosquera J; Martín-Subero JI; Granada I; Esteller M; Domingo-Domenech E; Climent F; Villanueva A; Sureda A
Dis Model Mech; 2021 Jul; 14(7):. PubMed ID: 33988237
[TBL] [Abstract][Full Text] [Related]
2. Whole-genome optical mapping of bone-marrow myeloma cells reveals association of extramedullary multiple myeloma with chromosome 1 abnormalities.
Kriegova E; Fillerova R; Minarik J; Savara J; Manakova J; Petrackova A; Dihel M; Balcarkova J; Krhovska P; Pika T; Gajdos P; Behalek M; Vasinek M; Papajik T
Sci Rep; 2021 Jul; 11(1):14671. PubMed ID: 34282158
[TBL] [Abstract][Full Text] [Related]
3. Role of FDG-PET/CT in Extramedullary Multiple Myeloma: Correlation of FDG-PET/CT Findings With Clinical Outcome.
Tirumani SH; Sakellis C; Jacene H; Shinagare AB; Munshi NC; Ramaiya NH; Van den Abbeele AD
Clin Nucl Med; 2016 Jan; 41(1):e7-13. PubMed ID: 26252323
[TBL] [Abstract][Full Text] [Related]
4. [Multiple myeloma with IgH::MYC and multiple extramedullary lesions].
Sasaki Y; Ichikawa S; Sakurai K; Nakamura H; Inokura K; Onodera K; Fukuhara N; Onishi Y; Yokoyama H; Harigae H
Rinsho Ketsueki; 2024; 65(3):147-152. PubMed ID: 38569857
[TBL] [Abstract][Full Text] [Related]
5. Beyond the marrow: insights from comprehensive next-generation sequencing of extramedullary multiple myeloma tumors.
Jelinek T; Zihala D; Sevcikova T; Anilkumar Sithara A; Kapustova V; Sahinbegovic H; Venglar O; Muronova L; Broskevicova L; Nenarokov S; Bilek D; Popkova T; Plonkova H; Vrana J; Zidlik V; Hurnik P; Havel M; Hrdinka M; Chyra Z; Stracquadanio G; Simicek M; Hajek R
Leukemia; 2024 Jun; 38(6):1323-1333. PubMed ID: 38493239
[TBL] [Abstract][Full Text] [Related]
6. Long non-coding RNA MALAT1 is an inducible stress response gene associated with extramedullary spread and poor prognosis of multiple myeloma.
Handa H; Kuroda Y; Kimura K; Masuda Y; Hattori H; Alkebsi L; Matsumoto M; Kasamatsu T; Kobayashi N; Tahara KI; Takizawa M; Koiso H; Ishizaki T; Shimizu H; Yokohama A; Tsukamoto N; Saito T; Murakami H
Br J Haematol; 2017 Nov; 179(3):449-460. PubMed ID: 28770558
[TBL] [Abstract][Full Text] [Related]
7. Anti-BCMA CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Single Center Analysis of Two Clinical Trials.
Que Y; Xu M; Xu Y; Almeida VDF; Zhu L; Wang Z; Wang Y; Liu X; Jiang L; Wang D; Li C; Zhou J
Front Immunol; 2021; 12():755866. PubMed ID: 34777368
[TBL] [Abstract][Full Text] [Related]
8. Research progress on treatment of extramedullary multiple myeloma.
Chen Y; Tao S; Zheng X; Shi Y; Zhang L; Chen K; He Z; Wang C; Yu L
Hematology; 2021 Dec; 26(1):985-994. PubMed ID: 34871523
[No Abstract] [Full Text] [Related]
9. How I treat extramedullary myeloma.
Touzeau C; Moreau P
Blood; 2016 Feb; 127(8):971-6. PubMed ID: 26679866
[TBL] [Abstract][Full Text] [Related]
10. Natural history, predictors of development of extramedullary disease, and treatment outcomes for patients with extramedullary multiple myeloma.
Zanwar S; Ho M; Lin Y; Kapoor P; Binder M; Buadi FK; Dispenzieri A; Dingli D; Fonder A; Gertz MA; Gonsalves W; Hayman SR; Hwa Y; Hobbs M; Kourelis T; Lacy MQ; Leung N; Muchtar E; Warsame R; Jevremovic D; Kyle RA; Rajkumar SV; Kumar S
Am J Hematol; 2023 Oct; 98(10):1540-1549. PubMed ID: 37421603
[TBL] [Abstract][Full Text] [Related]
11. Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial.
Mina R; Musto P; Rota-Scalabrini D; Paris L; Gamberi B; Palmas A; Aquino S; de Fabritiis P; Giuliani N; De Rosa L; Gozzetti A; Cellini C; Bertamini L; Capra A; Oddolo D; Vincelli ID; Ronconi S; Pavone V; Pescosta N; Cea M; Fioritoni F; Ballanti S; Grasso M; Zamagni E; Belotti A; Boccadoro M; Gay F
Lancet Oncol; 2023 Jan; 24(1):64-76. PubMed ID: 36528035
[TBL] [Abstract][Full Text] [Related]
12. Proteomic and Metabolomic Analysis of Bone Marrow and Plasma from Patients with Extramedullary Multiple Myeloma Identifies Distinct Protein and Metabolite Signatures.
Dunphy K; Bazou D; Henry M; Meleady P; Miettinen JJ; Heckman CA; Dowling P; O'Gorman P
Cancers (Basel); 2023 Jul; 15(15):. PubMed ID: 37568580
[TBL] [Abstract][Full Text] [Related]
13. FDA Approval Summary: Daratumumab for Treatment of Multiple Myeloma After One Prior Therapy.
Bhatnagar V; Gormley NJ; Luo L; Shen YL; Sridhara R; Subramaniam S; Shen G; Ma L; Shord S; Goldberg KB; Farrell AT; McKee AE; Pazdur R
Oncologist; 2017 Nov; 22(11):1347-1353. PubMed ID: 28904172
[TBL] [Abstract][Full Text] [Related]
14. Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib.
Nijhof IS; Groen RW; Noort WA; van Kessel B; de Jong-Korlaar R; Bakker J; van Bueren JJ; Parren PW; Lokhorst HM; van de Donk NW; Martens AC; Mutis T
Clin Cancer Res; 2015 Jun; 21(12):2802-10. PubMed ID: 25398450
[TBL] [Abstract][Full Text] [Related]
15. Venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory multiple myeloma harboring t(11,14)(q13;q32): two case reports and a review of the literature.
Abuelgasim KA; Alherz N; Alhejazi A; Damlaj M
J Med Case Rep; 2020 Apr; 14(1):54. PubMed ID: 32321588
[TBL] [Abstract][Full Text] [Related]
16. Cytogenetics in multiple myeloma patients progressing into extramedullary disease.
Besse L; Sedlarikova L; Greslikova H; Kupska R; Almasi M; Penka M; Jelinek T; Pour L; Adam Z; Kuglik P; Krejci M; Hajek R; Sevcikova S
Eur J Haematol; 2016 Jul; 97(1):93-100. PubMed ID: 26432667
[TBL] [Abstract][Full Text] [Related]
17. Successful Treatment of Relapsed/Refractory Extramedullary Multiple Myeloma With Anti-BCMA CAR-T Cell Therapy Followed by Haploidentical Hematopoietic Stem Cell Transplantation: A Case Report and a Review of the Contemporary Literature.
Qian Y; Qian Z; Zhao X; Pan W; Wei X; Meng H; Yang L; Xiao H
Front Med (Lausanne); 2021; 8():649824. PubMed ID: 34026784
[TBL] [Abstract][Full Text] [Related]
18. Expanded natural killer cells potentiate the antimyeloma activity of daratumumab, lenalidomide, and dexamethasone in a myeloma xenograft model.
Thangaraj JL; Jung SH; Vo MC; Chu TH; Phan MT; Lee KH; Ahn SY; Kim M; Song GY; Ahn JS; Yang DH; Kim HJ; Cho D; Lee JJ
Cancer Immunol Immunother; 2023 May; 72(5):1233-1246. PubMed ID: 36385211
[TBL] [Abstract][Full Text] [Related]
19. Extramedullary Multiple Myeloma: A Patient-Focused Review of the Pathogenesis of Bone Marrow Escape.
Gupta S; Master S; Graham C
World J Oncol; 2022 Oct; 13(5):311-319. PubMed ID: 36406195
[TBL] [Abstract][Full Text] [Related]
20. Multiple Extramedullary-Bone Related and/or Extramedullary Extraosseous Are Independent Poor Prognostic Factors in Patients With Newly Diagnosed Multiple Myeloma.
He J; Yue X; He D; Zhao Y; Yang Y; Zheng G; Zhang E; Han X; Wu W; Yang L; Chen J; Cai Z
Front Oncol; 2021; 11():668099. PubMed ID: 34307138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
